Tesaro Enters Immuno-Oncology Field With AnaptysBio Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Tesaro has plans to bring an anti-PD-1 agent into the clinic by mid-2015, with other immunotherapies to follow. The compounds will be products of AnaptysBio’s proprietary antibody platform.